Sector News

Haemonetics Expands Executive Management Roles To Complement Global Growth Strategy

April 28, 2015
Life sciences
/PRNewswire/ – Haemonetics Corporation announced today expanded roles for two executives.  These changes are part of an ongoing plan to advance the Company’s global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
 
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO.  In this expanded role, Mr. Davies will have overall accountability for the Company’s commercial, product development and product management focus across the entire portfolio and in all geographies. 
 
Byron Selman, who joined the Company upon the acquisition of Pall Corporation’s transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies.  Mr. Selman will oversee the Company’s global commercial and market development efforts, with the exception of the Company’s commercial Plasma business. 
 
Mr. Concannon stated: “Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers.  These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development.”
 
Source: Haemonetics

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach